| HOME >> BIOLOGY >> TECHNOLOGY |
PARIS, May 6 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, announces today the availability of its new SpliceArray(TM) for use in disease modeling and toxicogenomic applications by the basic and pre-clinical research communities. These SpliceArray(TM) products provide the highest resolution expression profiling analysis for the rat genome commercially available today. ExonHit's patented unique approach to detect all known and novel expressed transcripts is now offered through our portfolio of genomic services.
The Rat SpliceArray(TM) monitors over 23,000 genes utilizing over 200,000 exon body and 180,000 splice junction regions. This comprehensive coverage enables investigators to further elucidate the enormous diversity of the rat transcriptome. These new designs, manufactured on the Agilent Technologies and Affymetrix microarray platforms, now expand our product offering and enable researchers to leverage alternative splicing discovery in the rat model system.
"ExonHit continues to grow its catalog of arrays for it genomics services. This most recent addition will expand our ability to service clients who use rat models in elucidating disease biology, as well as for ExonHit's discovery collaboration programs for therapeutic targets and safety biomarkers," said John R. Jaskowiak, Executive Vice President of Molecular Diagnostics and Genomics Services at ExonHit Therapeutics.
"The addition of this model organism to the SpliceArray(TM) product
family further expands our presence in the expression profiling market. We
strongly believe that these new SpliceArray(TM) products will further
accelerate the understanding of mechanism of actions and ultimately the
discovery of new therapeutics while providing unprecedented toxicogenomics
data," stated Philippe Rousseau, Chairman of the Executive Board of ExonHit
Therapeutics. "Additionally, recent peer-reviewed publications in Canc
'/>"/>
| SOURCE ExonHit Therapeutics SA Copyright©2008 PR Newswire. All rights reserved |